Niagen Bioscience Reports Q3 Earnings Miss with Declining Revenue
Niagen Bioscience (NAGE) reported third-quarter financial results that fell short of market expectations. The company posted a GAAP earnings per share (EPS) of -$0.01, missing estimates by $0.01, while revenue reached $27.2 million, representing a 20% year-over-year decline and a miss of $4.7 million against consensus figures. Despite the quarterly shortfall, management provided forward-looking guidance for fiscal year 2026. The company anticipates direct website revenues to grow between 15% and 20% year-over-year, with overall e-commerce sales expected to increase by approximately 5%.
Topics: earnings miss financial guidance revenue decline
Read the full article at Seeking Alpha
Part of the story Diversified Healthcare Trust Reports Third Quarter FFO and Revenue Miss (5 articles)